Business Strategies

Strategies to Adapt and Succeed with Medtech M&A Valuations

Thursday, September 30, 2021

2:25 PM – 3:25 PM ET

Location: Virtual

Virtual Speaker(s)

Erich A. Wolff

Senior Vice President, Corporate Development & Strategy
BD
Charles Hamilton

Managing Director, Healthcare Investment Banking
Piper Sandler & Co.
Hasini Muthucumarana

Director Corporate Development
Medtronic

Virtual Moderator(s)

John Babitt

Partner, Life Sciences
EY

Virtual Speaker(s)

Paul LaViolette, MBA

Managing Partner, Chief Operating Officer
SV Health Investors

Continued strong sector fundamentals, improving end markets, new product launches and healthy pipelines has led to a significant run up in valuations of private and public medtech assets. As a result, organizations have been adopting new and more advanced valuation techniques to appropriately evaluate potential acquisitions - both from the buy and sell side. Officials from some of the most successful medtech organizations will share insights and best practices for capturing and analyzing the most relevant aspects in designing a comprehensive buy and sell side valuation for M&A and what challenges remain, including the following:
-How are companies succeeding in competitive situations for attractive targets?
-What are the right analytical tools for evaluating complex economics globally, including payer dynamics and commercial risks?
-What levels of strategic and operational diligence are required to properly value?
-How is the capital markets environment---cheap credit, activist shareholders - affecting resource allocation for transformative M&A?